810223C

C12-NBD Glucosyl Ceramide

Avanti Research^™ - A Croda Brand 810223C

• Synonym(e): N-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-D-glucosyl-β1-1′-sphingosine
• Empirische Formel (Hill-System): C₄₂H₇₁N₅O₁₁
• CAS-Nummer: 474943-01-6
• Molekulargewicht: 822.04
• MDL-Nummer: MFCD22570234
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Assay: >99% (TLC)
• Form: liquid
• Verpackung: pkg of 1 × 1 mL (810223C-250ug)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 810223C
• Konzentration: 0.25 mg/mL (810223C-250ug)
• Versandbedingung: dry ice
• Lagertemp.: −20°C

Beschreibung

Anwendung

C12-NBD Glucosyl Ceramide is suitable for liposome preparation.[1]

Biochem./physiol. Wirkung

Glucosyl ceramide (GlcCer) is produced by GlcCer synthase from ceramide in the cytosolic membranes of Golgi. In the luminal Golgi membrane, GlcCer participates in the generation of glycosphingolipids.[2]

Verpackung

5 mL Amber Glass Screw Cap Vial (810223C-250ug)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H302,H315,H319,H331,H336,H351,H361d,H372
• P-Sätze: P201 - P260 - P264 - P280 - P304 + P340 + P311 - P403 + P233
• Gefahreneinstufungen: Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
• Zielorgane: Central nervous system
• WGK: WGK 3